Cellnuo - Crunchbase Company Profile & Funding

Q: Where is Cellnuo's headquarters?

Cellnuo is located in Nanjing, Jiangsu, China.

Q: Who invested in Cellnuo?

Cellnuo has 2 investors including BGI Co-Win And Dongpingheng Investment.

Q: When was the last funding round for Cellnuo?

Cellnuo closed its last funding round on obfuscated from a Series A round.

Overview

Cellnuo

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Cellnuo

CB Rank

349551

Cellnuo develops pharmaceutical products to combat diabetes.

Founded

obfuscation

Private

Series A

Nanjing, Jiangsu, China

51-100

www.cellnuo.com/

Health Care

Medical

Pharmaceutical

Funding Rounds

Series A

OBF

obfuscation

Details

Legal Name

Nanjing Cellnuo Biotechnology Co., Ltd.

Operating Status

Active

Company Type

For Profit

About the Company

Cellnuo develops pharmaceutical products to help patients reduce the incidence of hypoglycemia and maintain healthier blood glucose levels, improving health outcomes for patients.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Icodec Insulin

A long-acting human insulin analog produced via recombinant DNA technology in E. coli, designed for once-weekly dosing by extending half-life through albumin binding.

Liraglutide

A recombinant GLP-1 analog produced by gene engineering in E. coli, used to stimulate insulin secretion and reduce glucagon in a glucose-dependent manner for type 2 diabetes treatment.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A

Funding Rounds

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Cellnuo	2	obfuscated obfuscation	—	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
BGI Co-Win	—	Series A - Cellnuo	—
BGI Co-Win	—	Series A - Cellnuo	—
BGI Co-Win	—	Series A - Cellnuo	—
BGI Co-Win	—	Series A - Cellnuo	—
BGI Co-Win	—	Series A - Cellnuo	—